...Health info at your doorstep

Day: 2 March 2021

Nigeria Receives First Batch of AstraZeneca COVAX Vaccines

Nigeria Receives First Batch of AstraZeneca COVAX Vaccines

NEWS
Nigeria has received the first batch of AstraZeneca vaccines from the COVAX Facility, the National Primary Health Care Development Agency says. So far, Nigeria is the third country in West Africa to receive the vaccines, coming after Ghana and Cote d’Ivoire. The country took delivery of the 3.92 million doses of vaccines on Tuesday [today] morning via the Nnamdi Azikwe International Airport, Abuja. In a tweet posted by the agency on its Twitter handle @Nphcda on Tuesday, it said “I AM HERE, NIGERIA!!! #YesToCOVID19Vaccine.” COVAX is co-led by Gavi, the Coalition for Epidemic Preparedness Innovations and WHO, which aims to accelerate the development and manufacture of COVID-19 vaccines and to guarantee fair and equitable access for every country in the world. The NPHCDA
New Coronavirus Variant: Here is What Scientists Know about B1525

New Coronavirus Variant: Here is What Scientists Know about B1525

NEWS
A coronavirus variant called B1525 has become one of the most recent additions to the global variant watch list and has been included in the list of variants under investigation by Public Health England. Scientists are keeping a watchful eye on this variant because it has several mutations in the gene that makes the spike protein – the part of the virus that latches onto human cells. These changes include the presence of the increasingly well-known mutation called E484K, which allows the virus to partly evade the immune system, and is found in the variants first identified in South Africa (B1351) and Brazil (P1). While there is no information on what this means for B1525, there is growing evidence that E484K may impact how effective COVID vaccines are. But there is no suggestion
NPHCDA Explains Phases of COVID-19 Vaccination

NPHCDA Explains Phases of COVID-19 Vaccination

NEWS
The Executive Director of the National Primary Health Care Development Agency, Dr. Faisal Shuaib, has explained the four phases of COVID-19 vaccination as scheduled. Shuaib disclosed this at the briefing of the Presidential Task Force on COVID-19 on Monday in Abuja. According to the NPHCDA chief, “Further to the clearance by NAFDAC, the PTF, Federal Ministry of Health, NPHCDA and strategic leaders will be at treatment center of the National Hospital on Friday March 5th 2021, where the first vaccination site will be set up to commence the vaccination of the frontline health workers and support staff. “These staff would also be electronically registered in the Covid-19 vaccine database and would receive their COVID-19 vaccination card which has a QR code that can be verified wor
Ensure COVID-19 vaccines Reach Right People, Not Politicians That Can Afford Them, NMA, NARD Tell FG

Ensure COVID-19 vaccines Reach Right People, Not Politicians That Can Afford Them, NMA, NARD Tell FG

NEWS
The Nigerian Medical Association and the National Association of Resident Doctors have urged the Federal Government not to politicise the COVID-19 vaccination. The medical associations advised the government to ensure that the vaccine gets to the people that need it, rather than politicians that can afford it. The NMA and NARD said the vaccines are meant for Nigerians and not for some special persons. The associations called for transparency in the distribution and prioritisation of COVID-19 vaccination in the country. They also stated that the COVID-19 vaccination should not be politicised, noting that the government must prioritise health workers who are the most at-risk of the viral infection. The NMA and the NARD made the call while speaking in separate interviews wi...
Hydroxychloroquine Has no Meaningful Effect on COVID-19 -WHO

Hydroxychloroquine Has no Meaningful Effect on COVID-19 -WHO

NEWS
  The World Health Organisation Guideline Development Group panel of international experts warns strongly against the use of hydroxychloroquine to prevent COVID-19. Their strong recommendation against the anti-inflammatory drug is based on high certainty evidence from six randomised controlled trials involving over 6,000 participants with and without known exposure to a person with COVID-19 infection, published in the journal, The British Medical Association. The experts noted that high certainty evidence showed that hydroxychloroquine had no meaningful effect on death and admission to hospital, while moderate certainty evidence showed that hydroxychloroquine had no meaningful effect on laboratory-confirmed COVID-19 infection and it probably increases the risk of adverse